TLSA (Tiziana Life Sciences) Total Operating Expense: $21.13 Mil (TTM As of Dec. 2025)


TLSA Tiziana Life Sciences Ltd TLSA
30 GF Score
Price $1.20
! 2 Warning Signs
View Full Analysis

What is Tiziana Life Sciences Total Operating Expense?

Tiziana Life Sciences TLSA +4.42% 30 Total Operating Expense is $21.13 Mil as of Dec. 2025. GuruFocus rates TLSA with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Tiziana Life Sciences's Total Operating Expense for the six months ended in Dec. 2025 was $11.95 Mil. Tiziana Life Sciences's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $21.13 Mil.

Tiziana Life Sciences Total Operating Expense Related Terms

Tiziana Life Sciences Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Tiziana Life Sciences's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tiziana Life Sciences Total Operating Expense Chart

Tiziana Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.37 14.59 17.98 15.79 21.13

Tiziana Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.29 6.51 9.29 9.19 11.95
TLSA
30GF Score
Tiziana Life Sciences Ltd TLSA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tiziana Life Sciences Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $21.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $21.13 Mil mean?
Tiziana Life Sciences (TLSA) has a Total Operating Expense of $21.13 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Tiziana Life Sciences and its competitors.
Is Tiziana Life Sciences' Total Operating Expense too high?
Tiziana Life Sciences' current Total Operating Expense is $21.13 Mil. Overall, Tiziana Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Tiziana Life Sciences' Total Operating Expense compare to DTIL and MIST?
Tiziana Life Sciences' Total Operating Expense of $21.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Tiziana Life Sciences and its competitors. Tiziana Life Sciences's current Total Operating Expense is $21.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tiziana Life Sciences stock overvalued right now?
Tiziana Life Sciences (TLSA) has a current Total Operating Expense of $21.13 Mil. The current Total Operating Expense is $21.13 Mil. Tiziana Life Sciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Tiziana Life Sciences (TLSA), the current Total Operating Expense is $21.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tiziana Life Sciences Business Description

Other Exchanges 0RP:Germany
Address 2 Church Street, Clarendon House, Hamilton, BMU, HM 11
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
30GF Score

Get the complete analysis for TLSA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.20
Price